International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8333307
Original Article
A Study on Association of Her2/neu and Ki - 67 Positivity with Extent of Disease in Breast Carcinoma
 ,
 ,
 ,
 ,
 ,
 ,
Published
Aug. 31, 2023
Abstract

Background: Breast carcinoma has become a serious threat worldwide, owing to the increasing incidence of the disease in both developing and developed countries.

Aims and objectives: To study the association between Her2/neu and Ki-67 values and the extent of disease in breast carcinoma.

Methods: This was a hospital based cross-sectional study conducted over the duration of 18 months. All the females admitted with breast cancer reporting the health facility were included in the study. Their detailed medical history, clinical information, and laboratory investigations were recorded in excel and analysed.

Results: Mean age of participants was found to be 49.12±10.64 years. 91.2% females were multiparous. History of breast feeding was reported in 88.2% females, 38.2% females had history of HRT/OCP intake and 32.4% females had positive history of chemoradiation for breast cancer. On histopathology. Majority (85.3%) of cancer were ductal carcinoma. PR, ER, Her2neu and Ki67 >14 expression was reported in 41.2%, 55.9%, 8.8% and 94.1% of findings respectively. 96.2%, 91.2% and 85.3 of grade 3 tumours reported Ki67 >14, Her2neu and Her2neu/Ki67 expressions respectively.

Conclusion: This study explored the association of Her2/neu and Ki-67 positivity with the extent of disease in breast carcinoma. Understanding various factors is essential for tailored management strategies and highlights the need for early detection and comprehensive screening programs to improve patient prognosis. Therefore, it is recommended that all individuals diagnosed with breast cancer should undergo testing for four specific markers.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
481 Views
332 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved